SAB Biotherapeutics (SABSW) Competitors $0.03 +0.00 (+2.89%) Closing price 06/2/2025 06:06 PM EasternExtended Trading$0.03 0.00 (0.00%) As of 06/2/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock SABSW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. SAB Biotherapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation. Does the media favor ATNFW or SABSW? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.89 beat SAB Biotherapeutics' score of 1.87 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive SAB Biotherapeutics Very Positive Does the MarketBeat Community prefer ATNFW or SABSW? 180 Life Sciences and SAB Biotherapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ASAB BiotherapeuticsN/AN/A Which has better valuation and earnings, ATNFW or SABSW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ASAB Biotherapeutics-$11.22MN/AN/AN/AN/A Is ATNFW or SABSW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A SAB Biotherapeutics N/A N/A N/A Summary180 Life Sciences beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABSW vs. The Competition Export to ExcelMetricSAB BiotherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$126.18M$5.45B$8.54BDividend YieldN/A3.74%5.26%4.19%P/E RatioN/A3.2927.1519.91Price / SalesN/A4,541.94449.30146.75Price / CashN/A13.1938.3234.64Price / BookN/A33.316.844.61Net IncomeN/A-$91.56M$3.24B$248.13M7 Day PerformanceN/A0.56%4.15%1.36%1 Month PerformanceN/A3.72%7.95%7.46%1 Year PerformanceN/A168.68%26.82%9.89% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSWSAB BiotherapeuticsN/A$0.03+2.9%N/A+27.5%$0.00$-11,221,976.000.00140Positive NewsGap DownATNFW180 Life SciencesN/A$0.01+2.5%N/A+1.0%$0.00N/A0.007Positive NewsGap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-90.7%$0.00N/A0.002High Trading VolumeAIMDWAinosN/A$0.12-42.4%N/AN/A$0.00$106,207.000.0040Gap UpALVOWAlvotechN/A$2.12+6.0%N/A-21.1%$0.00$585.60M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.01-18.0%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.09-18.1%N/AN/A$0.00$38.00M0.0070Positive NewsBTMDWbioteN/A$0.02-6.5%N/A-95.2%$0.00$199.38M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.10-9.0%N/A-82.9%$0.00N/A0.008News CoveragePositive NewsCELUWCelularityN/A$0.08+116.8%N/A+100.0%$0.00$54.22M0.00220Positive NewsGap Up Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABSW) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SABSW Stock Free SABSW Stock Alerts